Drugs and Devices

FDA approves Exjade to treat excess iron in patients with non-transfusion-dependent thalassemia

On Jan. 23, 2013, the U.S. Food and Drug Administration (FDA) approved the use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from non-transfusion-dependent thalassemia, a milder form of thalassemia. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares